213 related articles for article (PubMed ID: 31903899)
1. [Toxicities of immune checkpoint inhibitors and their management].
Kostine M; Marabelle A; Schaeverbeke T; Kfoury M
Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899
[TBL] [Abstract][Full Text] [Related]
2. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
3. [Next generation of anti-immune checkpoints antibodies].
Bonnefoy N; Olive D; Vanhove B
Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
[TBL] [Abstract][Full Text] [Related]
4. [The revolution of immuno-oncology therapy: review of immune checkpoint inhibitors efficacy].
Dubois M; Ardin C; André F; Scherpereel A; Mortier L
Med Sci (Paris); 2019 Dec; 35(12):937-945. PubMed ID: 31903897
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
7. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
8. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
[TBL] [Abstract][Full Text] [Related]
9. [Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].
Faviez G; Bousquet E; Rabeau A; Rouquette I; Collot S; Goumarre C; Meyer N; Prevot G; Mazieres J
Rev Mal Respir; 2018 Nov; 35(9):963-967. PubMed ID: 30220489
[TBL] [Abstract][Full Text] [Related]
10. Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?
Percik R; Shoenfeld Y
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101411. PubMed ID: 32278687
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Postow MA; Sidlow R; Hellmann MD
N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
[No Abstract] [Full Text] [Related]
12. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
[TBL] [Abstract][Full Text] [Related]
14. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
[TBL] [Abstract][Full Text] [Related]
15. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
[TBL] [Abstract][Full Text] [Related]
16. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].
Szekanecz É; Szekanecz Z
Orv Hetil; 2019 Jun; 160(23):887-895. PubMed ID: 31155880
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
Lewis AL; Chaft J; Girotra M; Fischer GW
Br J Anaesth; 2020 Mar; 124(3):251-260. PubMed ID: 32007241
[TBL] [Abstract][Full Text] [Related]
19. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
20. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]